These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 36080069)
1. Nanocrystal Suspensions for Enhancing the Oral Absorption of Albendazole. Liang Z; Chen M; Yan Y; Chen D; Xie S Nanomaterials (Basel); 2022 Sep; 12(17):. PubMed ID: 36080069 [TBL] [Abstract][Full Text] [Related]
2. Improvement of Albendazole Bioavailability with Menbutone Administration in Sheep. Diez R; Diez MJ; Garcia JJ; Rodríguez JM; Lopez C; Fernandez N; Sierra M; Sahagun AM Animals (Basel); 2022 Feb; 12(4):. PubMed ID: 35203171 [TBL] [Abstract][Full Text] [Related]
3. Improving the Solubility, Stability, and Bioavailability of Albendazole through Synthetic Salts. Yan H; Zhong X; Liu Y Molecules; 2024 Jul; 29(15):. PubMed ID: 39124976 [TBL] [Abstract][Full Text] [Related]
4. Disposition kinetics of albendazole and metabolites in laying hens. Bistoletti M; Alvarez L; Lanusse C; Moreno L J Vet Pharmacol Ther; 2013 Apr; 36(2):161-8. PubMed ID: 22533477 [TBL] [Abstract][Full Text] [Related]
5. Determination of albendazole and metabolites in silkworm Bombyx mori hemolymph by ultrafast liquid chromatography tandem triple quadrupole mass spectrometry. Li L; Xing DX; Li QR; Xiao Y; Ye MQ; Yang Q PLoS One; 2014; 9(9):e105637. PubMed ID: 25255321 [TBL] [Abstract][Full Text] [Related]
6. A combined in vitro in-silico approach to predict the oral bioavailability of borderline BCS Class II/IV weak base albendazole and its main metabolite albendazole sulfoxide. Pettarin M; Bolger MB; Chronowska M; Kostewicz ES Eur J Pharm Sci; 2020 Dec; 155():105552. PubMed ID: 32937212 [TBL] [Abstract][Full Text] [Related]
7. Phospholipid Complexation for Bioavailability Improvement of Albendazole: Preparation, Characterization and In Vivo Evaluation. Liu L; Nie J; Li L AAPS PharmSciTech; 2023 Jan; 24(1):36. PubMed ID: 36635447 [TBL] [Abstract][Full Text] [Related]
8. Albendazole Nanocrystal-Based Dissolving Microneedles with Improved Pharmacokinetic Performance for Enhanced Treatment of Cystic Echinococcosis. Permana AD; Paredes AJ; Zanutto FV; Amir MN; Ismail I; Bahar MA; Sumarheni ; Palma SD; Donnelly RF ACS Appl Mater Interfaces; 2021 Aug; 13(32):38745-38760. PubMed ID: 34353029 [TBL] [Abstract][Full Text] [Related]
9. Improvement of Antialveolar echinococcosis efficacy of novel Albendazole-Bile acids Derivatives with Enhanced Oral Bioavailability. Hu C; Qin M; Zhang F; Gao R; Gan X; Du T PLoS Negl Trop Dis; 2023 Jan; 17(1):e0011031. PubMed ID: 36595544 [TBL] [Abstract][Full Text] [Related]
10. Improvement of Antialveolar Echinococcosis Efficacy of Albendazole by a Novel Nanocrystalline Formulation with Enhanced Oral Bioavailability. Hu C; Liu Z; Liu C; Zhang Y; Fan H; Qian F ACS Infect Dis; 2020 May; 6(5):802-810. PubMed ID: 31576751 [TBL] [Abstract][Full Text] [Related]
11. Stereospecific biotransformation of albendazole in mouflon and rat-isolated hepatocytes. Velík J; Baliharová V; Skálová L; Szotáková B; Wsól V; Lamka J J Vet Pharmacol Ther; 2003 Aug; 26(4):297-302. PubMed ID: 12887613 [TBL] [Abstract][Full Text] [Related]
12. Comparative plasma disposition kinetics of albendazole, fenbendazole, oxfendazole and their metabolites in adult sheep. Lanusse CE; Gascon LH; Prichard RK J Vet Pharmacol Ther; 1995 Jun; 18(3):196-203. PubMed ID: 7674455 [TBL] [Abstract][Full Text] [Related]
13. Albendazole solid dispersions prepared using PEG6000 and Poloxamer188: formulation, characterization and Dong CL; Zheng SD; Liu YY; Cui WQ; Hao MQ; God'spower BO; Chen XY; Li YH Pharm Dev Technol; 2020 Nov; 25(9):1043-1052. PubMed ID: 32546042 [TBL] [Abstract][Full Text] [Related]
14. New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. Permana AD; Tekko IA; McCarthy HO; Donnelly RF J Pharm Biomed Anal; 2019 Jun; 170():243-253. PubMed ID: 30947125 [TBL] [Abstract][Full Text] [Related]
15. Studies on absorption mechanism and pharmacokinetic properties of albendazole-bile acid conjugate: In vivo and in vitro. Guo Z; Tang S; Nie K; Liu J; Hu C Biomed Pharmacother; 2024 Oct; 179():117400. PubMed ID: 39243427 [TBL] [Abstract][Full Text] [Related]
16. Exploitation of nanocrystal suspension as an effective oral formulation for oxfendazole. Sun Y; Chen D; Zhao Y; Zhou K; Zhang B; Wang H; Xie S Drug Deliv Transl Res; 2022 May; 12(5):1219-1229. PubMed ID: 34148210 [TBL] [Abstract][Full Text] [Related]
17. Fasting-induced changes to the pharmacokinetic behaviour of albendazole and its metabolites in calves. Sánchez SF; Alvarez LI; Lanusse CE J Vet Pharmacol Ther; 1997 Feb; 20(1):38-47. PubMed ID: 9049948 [TBL] [Abstract][Full Text] [Related]
18. Enhanced Solubility of Albendazole in Cyclodextrin Inclusion Complex: A Molecular Modeling Approach and Physicochemical Evaluation. de Melo CG; da Costa LAG; Rabello MM; de Albuquerque Wanderley Sales V; Ferreira AS; da Silva PCD; Nishimura RHV; da Silva RMF; de Araújo Rolim L; Neto PJR Curr Drug Deliv; 2022; 19(1):86-92. PubMed ID: 34126897 [TBL] [Abstract][Full Text] [Related]
19. Methimazole-mediated enhancement of albendazole oral bioavailability and anthelmintic effects against parenteral stages of Trichinella spiralis in mice: the influence of the dose-regime. López-García ML; Torrado S; Torrado S; Martínez AR; Bolás F Vet Parasitol; 1998 Feb; 75(2-3):209-19. PubMed ID: 9637222 [TBL] [Abstract][Full Text] [Related]
20. Effect of amphiphilic surfactant agents on the gastrointestinal absorption of albendazole in cattle. Virkel G; Imperiale F; Lifschitz A; Pis A; Alvarez A; Merino G; Prieto J; Lanusse C Biopharm Drug Dispos; 2003 Apr; 24(3):95-103. PubMed ID: 12673667 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]